Gabe S. Sonke

Active 1996–2026

Also published as
Gabe S Sonke
163
Papers
29,896
Citations
67
h-index
148
i10-index

Citations

Citations per year for Gabe S. Sonke1964: 2 citations1993: 1 citations1997: 1 citations1998: 1 citations1999: 3 citations2000: 3 citations2001: 3 citations2003: 2 citations2004: 8 citations2005: 4 citations2006: 8 citations2007: 5 citations2008: 8 citations2009: 3 citations2010: 8 citations2011: 6 citations2012: 7 citations2013: 8 citations2014: 15 citations2015: 25 citations2016: 63 citations2017: 124 citations2018: 195 citations2019: 1,022 citations2020: 1,507 citations2021: 1,578 citations2022: 1,466 citations2023: 1,409 citations2024: 2,232 citations2025: 1,105 citations2026: 35 citations1965–1992: no citations, so these years are not shown1994–1996: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,952 citing papers, 20.5% of this breakdownChina: 1,274 citing papers, 8.9% of this breakdownItaly: 942 citing papers, 6.5% of this breakdownUnited Kingdom: 925 citing papers, 6.4% of this breakdownFrance: 698 citing papers, 4.9% of this breakdownGermany: 692 citing papers, 4.8% of this breakdownNetherlands: 618 citing papers, 4.3% of this breakdownSpain: 585 citing papers, 4.1% of this breakdownCanada: 563 citing papers, 3.9% of this breakdownAustralia: 483 citing papers, 3.4% of this breakdownBelgium: 374 citing papers, 2.6% of this breakdownJapan: 372 citing papers, 2.6% of this breakdown
0%20.5%Other 27.1%

Fields

  • Medicine70.4%
  • Biochemistry, Genetics and Molecular Biology23.6%
  • Immunology and Microbiology2.5%
  • Engineering0.8%
  • Computer Science0.7%
  • Materials Science0.4%
  • Other1.6%

Topics

  • Advanced Breast Cancer Therapies6.4%
  • PARP inhibition in cancer therapy6.3%
  • Ovarian cancer diagnosis and treatment5.7%
  • Breast Cancer Treatment Studies4.8%
  • Cancer Immunotherapy and Biomarkers3.8%
  • HER2/EGFR in Cancer Research3.4%
  • Other69.6%

Coauthors

All papers

Open in search
  1. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 2,839

  2. AACR Project GENIE: Powering Precision Medicine through an International Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefèbvre, Michele L. Lenoue-Newton, Eva M. Lepisto, Mia Levy, Neal I. Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E. MacConaill, Ian Maurer, David S. Maxwell, Gerrit A. Meijer, Funda Meric‐Bernstam, Christine Micheel, Clinton Miller, Gordon B. Mills, Nathanael D. Moore, Petra M. Nederlof, Larsson Omberg, John A. Orechia, Ben Ho Park, Trevor J. Pugh, Brendan Reardon, Barrett J. Rollins, Mark J. Routbort, Charles L. Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna Shaw, Priyanka Shivdasani, Lillian L. Siu, David B. Solit, Gabe S. Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie Stickle, Thomas Stricker, Shawn M. Sweeney, Barry S. Taylor, Jelle J. ten Hoeve, Stacy B. Thomas, Eliezer M. Van Allen, Laura van ‘t Veer, Tony van de Velde, Harm van Tinteren, Victor E. Velculescu, Carl Virtanen, Emile E. Voest, Lucy Lu Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang - Cancer Discovery 2017 cited by 2,004

  3. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 713

  4. openalex_id:w4221085715

    Authors: , , , , , , , , , , , , , , , , , , , cited by 579

  5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson and 21 more - The Lancet Oncology 2017 cited by 1,863

  6. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 cited by 2,009

  7. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sabine C. Linn, Ton N. Schumacher, Christian U. Blank, Marleen Kok - Nature Medicine 2019 cited by 889

  8. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Authors: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 cited by 840

  9. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 475

  10. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 1,112

  11. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen Y. Chui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Angela M. DeMichele, Xiuzhen Duan, Kirsten K. Edmiston, Anthony D. Elias, Erin D. Ellis, Laura L. Esserman, David M. Euhus, Oluwole Fadare, Fang Fan, Michael D Feldman, Andres Forero-Torres, Barbara B. Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly E. Klein, Gregor Krings, Julie E. Lang, Lauren G. LeBeau, Brian Leyland-Jones, Minetta C. Liu, Shelly Lo, Janice Lu, Anthony Magliocco, Jeffrey B. Matthews, Michelle E. Melisko, Paulette Mhawech-Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris T. Ocal, Olufunmilayo Olopade, Stefan Pambuccian, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Garry Peterson, Lajos Pusztai, Mara Rendi, Hope S. Rugo, Sunati Sahoo, Sharon Sams, Ashish Sanil, Husain Sattar, Richard B. Schwab, Ruby Singhrao, Katherine Steeg, Erica Stringer-Reasor, W. Fraser Symmans, Ossama Tawfik, Debasish Tripathy, Megan L. Troxell, Laura J. van't Veer, Sara J. Venters, Tuyethoa Vinh, Rebecca K. Viscusi, Anne M. Wallace and 37 more - The Lancet Oncology 2021 cited by 437

  12. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke and 509 more - Annals of Oncology 2022 cited by 447

  13. openalex_id:w4200350191

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen‐John Sammut, Jeremy Thomas, David Cameron, A Graham, Peter S Hall, Lorna Mackintosh, Fang Fan, Andrew K. Godwin, Kelsey Schwensen, Priyanka Sharma, Angela DeMichele, Kimberly Cole, Lajos Pusztai, Mi‐Ok Kim, Laura van ‘t Veer, Laura Esserman, W. Fraser Symmans, Kathi Adamson, Kathy S. Albain, Adam L. Asare, Smita Asare, Ronald Balassanian, Heather Beckwith, Scott Berry, Donald A. Berry, Meredith Buxton, Yunn‐Yi Chen, Beiyun Chen, A. Jo Chien, Jane Yuet Ching Hui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Xiuzhen Duan, Kirsten K. Edmiston, Anthony Elias, Erin D. Ellis, David Euhus, Oluwole Fadare, Michael D. Feldman, Andres Forero‐Torres, Barbara Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly Klein, Gregor Krings, Julie E. Lang, Lauren LeBeau, Brian Leyland‐Jones, Minetta C. Liu, Shelly S. Lo, Janice Lu, Anthony M. Magliocco, Jeffrey B. Matthews, Michelle Melisko, Paulette Mhawech‐Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris Tolgay Ocal, Olufunmilayo I. Olopade and 28 more cited by 353

  14. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2018 cited by 868

  15. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 841

  16. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,409

  17. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 371

  18. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  19. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 445

  20. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 278

  21. openalex_id:w4226283539

    Authors: , , , , , , , , , , , , , , , , , , cited by 185

  22. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 cited by 154

  23. Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 657

  24. Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martina E. Schmidt, Karin Potthoff, Marc van Beurden, Hester S. A. Oldenburg, Gabe S. Sonke, Wim H. van Harten, Rachel Garrod, Kathryn H. Schmitz, Kerri M. Winters‐Stone, Miranda J. Velthuis, Dennis R. Taaffe, Willem van Mechelen, Marie José Kersten, Frans Nollet, Jennifer Wenzel, Joachim Wiskemann, Irma M. Verdonck‐de Leeuw, Johannes Brug - Cancer Treatment Reviews 2016 cited by 610